The ophthalmological equipment track is favored and is expected to see rapid development in the future.

Pharmaceutical Network Market Analysis: Recently, the medical device sector is still attracting market attention, in addition to orthopaedics, IVD and other sub-sectors, ophthalmological devices this sub-industry is also being favored by the industry.
it is understood that the global medical device industry, the top five areas, including in vitro diagnosis, cardiovascular, medical imaging, orthopaedics and ophthalmology, accounting for 13%, 12%, 10%, 9%, 7%, ophthalmology ranked in the top five.
in China's medical device industry, the top five areas are medical medical equipment (39%), household medical equipment (18%), low-value consumables (12%), in vitro diagnosis (11%) and vascular intervention (7%), ophthalmology currently accounted for only 1%.
with the continuous upgrading of China's medical consumption level, as well as femto second surgery, optical services, corneal plastic mirror, artificial crystals, glass body and other new surgical development, the industry believes that the future of China's ophthalmology gold track is expected to usher in rapid development.
is optimistic about leading enterprises Aibo Medical, Bohai Health and so on.
Aibo Medical: Ophthalmology equipment innovation-oriented enterprise Siebo Medical is about to land on the board, is currently the rare domestic eye medical device field investment target.
company's main products cover surgery and optical two areas, mainly for cataracts and refractive imshouldch two categories caused by blinding and vision impairment of the main eye diseases, at this stage in the field of ophthalmology surgery core products for artificial crystals, the core products in the field of optometrists for corneal plastic mirrors.
2014, Ebo Medical launched the first collapsible aspherical artificial crystal, the current artificial crystal has 20 product models, covering more than 1000 hospitals in China, and exported to More than 10 countries in Asia, Europe and the Americas, a cumulative sales of nearly 1 million tablets.
over the past three years, Aibo Medical's artificial crystals have maintained a high growth rate, with a compound annual growth rate of 65.6%.
with the aging of the domestic, the prevalence of cataracts, as well as consumption upgrade, is expected to promote the artificial crystal industry continue to expand capacity, the industry is expected to grow by 10% in the next five years. in addition,
, the current artificial crystal market foreign investment still dominates, domestic share of less than 20%, with the further promotion of volume procurement, the company is expected to expand market share.
industry believes that with the continued expansion of the artificial crystal industry and import substitution, the company's products are expected to maintain more than 20% of the compound growth in the next three years.
March 2019, Aibo Medical obtained the corneal plastic mirror product registration certificate, becoming the second approved enterprise in Chinese mainland, the current product is in the early stage of release.
about 100 million young people in China are short-sighted patients, corneal plastic mirror can effectively delay the process of myopia, the industry space is vast, with the continuous improvement of penetration rate, it is expected that the 2025 corneal plastic mirror market space will exceed 4.6 billion yuan.
and Aibo medical products have a relative competitive advantage, the industry expects the next three years the corneal mirror is expected to quickly occupy the market, sales revenue of more than 100 million yuan in 2022.
Bohai Health Department: domestic ophthalmology supplies leader Bohai Health Department in 2019 eye revenue accounted for about 45%, the industry believes that mirror, corneal plastic mirror, artificial glass body is expected to drive the company's rapid growth in eye revenue, in addition to artificial crystal will further enhance market share.
in respect of the mirror, the company through the holding of Hangzhou Ai Jinglun (55% equity), included in its mirror PRL for the correction of myopia surgery.
with the future penetration of the mirror increase, the company's market space is larger.
in the corneal plastic mirror, the current corneal plastic mirror penetration rate of only about 1%, the company in the research products have a significant high oxygen permeability advantage, is expected to accompany the penetration rate increase, after the market to accelerate domestic substitution.
, the company's new artificial glass body is in the preclinical research stage, is expected to achieve a technical breakthrough in fillers, artificial crystals are affected by the collection policy to accelerate industry integration, the company through continuous layout, the market share is expected to increase.
.